Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 109 publications

First case report of talquetamab use in AL amyloidosis.

First case report of talquetamab use in AL amyloidosis.

Journal: Leukemia & lymphoma
Published: October 16, 2025

Correction to "Understanding quality of life under talquetamab: Learning to measure what matters".

Correction to "Understanding quality of life under talquetamab: Learning to measure what matters".

Journal: Cancer
Published: October 13, 2025

Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up Doses.

Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up Doses.

Journal: JCO oncology practice
Published: September 16, 2025

Managing side effects of talquetamab for relapsed/ refractory multiple myeloma in MonumenTAL- 1: a plain language summary.

Managing side effects of talquetamab for relapsed/ refractory multiple myeloma in MonumenTAL- 1: a plain language summary.

Journal: Future oncology (London, England)
Published: September 15, 2025

Dermatological safety of humanized bispecific antibody Talquetamab: skin and nail adverse events related to a novel immunotherapy for multiple myeloma.

Dermatological safety of humanized bispecific antibody Talquetamab: skin and nail adverse events related to a novel immunotherapy for multiple myeloma.

Journal: Italian journal of dermatology and venereology
Published: September 10, 2025

Understanding quality of life under talquetamab: Learning to measure what matters.

Understanding quality of life under talquetamab: Learning to measure what matters.

Journal: Cancer
Published: August 26, 2025

Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers.

Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers.

Journal: Seminars in hematology
Published: August 21, 2025

Safety and Efficacy of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials.

Safety and Efficacy of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials.

Journal: Cancers
Published: August 05, 2025

Highlights from the European Hematology Association Congress 2025.

Highlights from the European Hematology Association Congress 2025.

Journal: Acta haematologica
Published: July 21, 2025

Neurologic Adverse Events Associated With T-cell Engager Therapy in Multiple Myeloma: A Pharmacovigilance Study.

Neurologic Adverse Events Associated With T-cell Engager Therapy in Multiple Myeloma: A Pharmacovigilance Study.

Journal: Cureus
Published: July 14, 2025

Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline.

Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: July 13, 2025

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; nivolumab plus ipilimumab for hepatocellular carcinoma, fedratinib for myelofibrosis, talquetamab for multiple myeloma, and belzutifan for tumors associated with von Hippel-Lindau disease and renal cell carcinoma.

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; nivolumab plus ipilimumab for hepatocellular carcinoma, fedratinib for myelofibrosis, talquetamab for multiple myeloma, and belzutifan for tumors associated with von Hippel-Lindau disease and renal cell carcinoma.

Journal: International journal of clinical oncology
Published: July 11, 2025
Showing 1-12 of 109

Last Updated: 10/31/2025